At March 17, 2019: The American Heart Association
(AHA) and the American College of Cardiology (ACC) released a new guideline for
the primary prevention of cardiovascular disease.
Mubashar A Choudry MD |
Mubashar A. Choudry M.D., F.A.C.C., Chief
Medical Officer, Washington Cardiovascular Institute designates this guideline
as a “one-stop-shop” for accurate information in the primary prevention of
cardiovascular disease.
According to Dr. Choudry, there are four main takeaways
from this guideline, which draws largely on the trials mentioned in the previous
blog post- Nix Daily Low-Dose Aspirin –
ARRIVE, ASCEND, and ASPREE – the main being that Aspirin isn’t a good
preventative medication for reducing risk of cardiovascular disease in most
cases.
Mubashar A Choudry |
The new guideline downgraded aspirin as an
effective primary prevention method for cardiovascular disease, even giving it
a Class III recommendation in two cases, meaning that in these cases, a low
dose of aspirin (75-100 mg daily) could result in harm to the patient. Dr.
Choudry also notes that these trials suggest that the risk of bleeding caused
by daily low-dose aspirin seems to outweigh the chances that it prevents a cardiovascular event such as a heart attack.
Low Dose Aspirin for heart |
And
while this updated ruling on the risks of daily low-dose aspirin may be seen as
controversial by some reviewing the new guideline, Dr. Choudry stands by the updated ruling, citing the clinical trials and evidence-based studies that this
primary prevention method for cardiovascular disease is not necessarily as safe
or effective as it has historically been thought to be.
Comments
Post a Comment